CLARITY Trial

The CLARITY study aims to look at the development of antibodies to SARS-CoV-2 (the virus that causes COVID-19) in UK patients with Crohn's and Colitis (the two main forms of Inflammatory Bowel Disease (IBD)).

What will the study look at?

Researchers will test samples from people taking different Crohn's and Colitis drugs, which have been collected since the start of 2020, for antibodies against SARS-CoV-2. They will then follow how these people get on over the next 12 months.

What to they hope to find out?

  • Provide insights into which people with Crohn's or Colitis are at risk of COVID-19 infection,
  • To better understand the impact of Crohn's and Colitis medications on developing protective antibodies against the SARS-CoV-2 virus,
  • Build evidence about safer prescribing of immunomodulator and biologic drugs in the COVID-19 era, and
  • Inform public health policy on vaccination strategies.

Although this study will define risk in people in Crohn's and Colitis, there are potentially important lessons to be learned for millions of patients across the UK with other immune mediated diseases treated with similar therapies.

How can I take part?

The team would be really interested to hear from patients taking infliximab or vedolizumab to take part in this work. Importantly, as the pandemic continues you can take part safely from your infusion ward or even remotely by taking your own finger-prick test! 

The team are dedicated to considering patient priorities throughout the project. For example, they found that participants were keen to receive the results of their coronavirus antibody tests and so the researchers have committed to providing these throughout the course of the study. It is for this reason that Crohn's & Colitis are so proud to be partners in this important trial to help represent the patient voice.

If you would like to get involved, please speak to your IBD team to see if your hospital is taking part. If your hospital isn't yet part of the trial, you can suggest it to your IBD team.

You can find out all the latest details about the study on the CLARITY IBD website.

Start date: Recruitment started in summer 2020

End date: The study will continue throughout 2020 and 2021, but recruitment closes 23rd December 2020.

When will the findings of this work come out? The results of the first stage of the study will be available from 30th Decemeber 2020, then the second stage of findings will be available from 30th August 2021.

Lead researcher: Dr Tariq Ahmad (Royal Devon & Exeter Hospital)